Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

HI Cprevent logo small


This award-winning blog supplements the articles in Hospital Infection Control & Prevention.

Whapping VAP in the developing world

Adding a bundle of low-cost interventions to surveillance significantly reduces rates of ventilator-associated pneumonia (VAP) in intensive care units in developing countries, researchers found in an international study featured in published reports.

"This study is among the first few that have reported a substantial reduction in VAP rates in the ICU setting, proving the success of this kind of infection-control approach," say Victor Rosenthal (International Nosocomial Infection Control Consortium [INICC], Buenos Aires, Argentina) and colleagues.

"VAP control may not be sufficient or feasible if a single measure is implemented, but it requires a culture change involving the entire ICU team," they write in Critical Care Medicine. "Similarly, a reduction in VAP rates cannot be expected to derive from surveillance itself, unless the collection of data is used for the improvement of patient-care practices, such as performance feedback."

The authors used data from 55,507 AICU patients in hospitals involved in the INICC surveillance program in 14 developing countries (Argentina, Brazil, China, Colombia, Costa Rica, Cuba, India, Lebanon, Macedonia, Mexico, Morocco, Panama, Peru, and Turkey).

During the baseline phase, centers began the surveillance program for 3 months. In the second phase, which lasted a mean of 35.2 months, additional measures were introduced, such as hand hygiene protocol, minimizing duration of ventilation, and antiseptic oral care, combined with performance feedback.

The authors found that between baseline and the end of the intervention period, the rate of VAP significantly decreased from 22.0 infections per 1000 mechanoventilated‑days to 17.2 infections per 1000 mechanoventilated‑days.

Adjusted analyses showed that between the start and end of the second phase, the VAP rate decreased by 55.8%.